Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.82 |
| ▸ | RAF1 | P04049 | 8/20 | 0.82 |
| ▸ | KDR | P35968 | 7/20 | 0.82 |
| ▸ | RET | P07949 | 3/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.82 |
| ▸ | ABL1 | P00519 | 2/20 | 0.82 |
| ▸ | HTR1A | P08908 | 2/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.82 |
| ▸ | KIT | P10721 | 2/20 | 0.82 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.82 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.82 |
| ▸ | FLT1 | P17948 | 2/20 | 0.82 |
| ▸ | MAOA | P21397 | 2/20 | 0.82 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.82 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.82 |
| ▸ | TTK | P33981 | 2/20 | 0.82 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432444 | 0.92 | RAF1 (0.82) | BRAFRAF1KDRRETRIPK2 | |
| SCHEMBL29643339 | 0.92 | RAF1 (0.82) | BRAFRAF1KDRRETRIPK2 | |
| SCHEMBL22627130 | 0.91 | RAF1 (0.85) | BRAFRAF1KDRRETRIPK2 | |
| SCHEMBL12333608 | 0.91 | RAF1 (0.82) | BRAFRAF1KDRRETRIPK2 | |
| SCHEMBL29793192 | 0.90 | RAF1 (0.83) | BRAFRAF1KDRRETRIPK2 | |
| SCHEMBL3408499 | 0.90 | RAF1 (0.83) | BRAFRAF1KDRRETRIPK2 | |
| Regorafenib SCHEMBL29349808 | 0.90 | RAF1 (1.00) | BRAFRAF1KDRRETRIPK2 | |
| Regorafenib SCHEMBL29351376 | 0.90 | RAF1 (1.00) | BRAFRAF1KDRRETRIPK2 | |
| Regorafenib SCHEMBL432230 | 0.90 | RAF1 (1.00) | BRAFRAF1KDRRETRIPK2 | |
| Regorafenib SCHEMBL2555101 | 0.89 | RAF1 (0.98) | BRAFRAF1KDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117899212-A | Combination of regorafenib and a PD-1/PD-L1 (2) inhibitor for the treatment of cancer | 拜耳医药保健有限责任公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117582495-A | Combination of regorafenib and a PD-1/PD-L1 (2) inhibitor for the treatment of cancer | 拜耳医药保健有限责任公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-110662540-B | Combination of regorafenib and a PD-1/PD-L1 (2) inhibitor for the treatment of cancer | 拜耳医药保健有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116392485-A | Coated pharmaceutical composition containing regorafenib | 拜尔健康护理有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116392598-A | Coated pharmaceutical composition containing regorafenib | 拜尔健康护理有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116392484-A | Coated pharmaceutical composition containing regorafenib | 拜尔健康护理有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-3513809-B9 | MEDICINAL COMPOSITION COMPRISING TIVOZANIB | KYOWA KIRIN CO LTD (JP) | 2022-07-13 | — | — | EP | disclosed |
| EP-4000634-A1 | MEDICINAL COMPOSITION COMPRISING TIVOZANIB | Kyowa Kirin Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| US-11078232-B2 | Preparation and use of molecular site targeted and activated kinase inhibitor | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200140485-A1 | PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. (CN) | 2020-05-07 | — | — | US | disclosed |
| US-20130060043-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD (CN) | 2013-03-07 | — | — | US | disclosed |
| EP-2562159-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2013-02-27 | — | — | EP | disclosed |
| EP-2562159-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2013-02-27 | — | — | EP | disclosed |
| CN-102803220-A | Synthetic method of fluorine-containing deuterated diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD | 2012-11-28 | — | — | CN | disclosed |
| WO-2011113368-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | 苏州泽璟生物制药有限公司 (CN) | 2011-09-22 | — | — | WO | disclosed |
| CN-101287463-A | Novel pharmaceutical compositions comprising 4- (4- (3- (4-chloro-3-trifluoromethylphenyl) -ureido) -3-fluorophenoxy) -pyridine-2-carboxylic acid for the treatment of hyperproliferative diseases | BAYER PHARMACEUTICAL CORP (US) | 2008-10-15 | — | — | CN | disclosed |
| EP-1948170-A1 | DIARYL UREA FOR TREATING PULMONARY HYPERTENSION | Bayer HealthCare AG (DE) | 2008-07-30 | — | — | EP | disclosed |
| EP-1793824-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING 4-(4-(3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-UREIDO)-3-FLUORO-PHENOXY)-PYRIDINE-2-CARBOXYLIC ACID FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007054216-A1 | DIARYL UREA FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006026500-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING 4-(4-(3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-UREIDO)-3-FLUORO-PHENOXY)-PYRIDINE-2-CARBOXYLIC ACID FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060043-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | CCND3, UBE2D3, VDR | BRAF 1533/4885RAF1 3715/4885KDR 4466/4885 |
| US-11078232-B2 | Preparation and use of molecular site targeted and activated kinase inhibitor | ACP1, PACSIN2, PKN2 | BRAF 108/4885RAF1 127/4885KDR 1924/4885 |
| US-20200140485-A1 | PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR | ACP1, PACSIN2, PKN2 | BRAF 123/4885RAF1 122/4885KDR 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.